Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Convertible Debt (2022 - 2025)

Coeptis Therapeutics Holdings has reported Convertible Debt over the past 4 years, most recently at $218750.0 for Q1 2025.

  • Quarterly results put Convertible Debt at $218750.0 for Q1 2025, changed N/A from a year ago — trailing twelve months through Mar 2025 was $218750.0 (changed N/A YoY), and the annual figure for FY2024 was $218750.0, down 65.0%.
  • Convertible Debt for Q1 2025 was $218750.0 at Coeptis Therapeutics Holdings, roughly flat from $218750.0 in the prior quarter.
  • Over the last five years, Convertible Debt for COEPW hit a ceiling of $625000.0 in Q4 2023 and a floor of $58100.0 in Q3 2022.
  • Median Convertible Debt over the past 4 years was $218750.0 (2024), compared with a mean of $244720.0.
  • Peak annual rise in Convertible Debt hit 65.0% in 2024, while the deepest fall reached 65.0% in 2024.
  • Coeptis Therapeutics Holdings' Convertible Debt stood at $58100.0 in 2022, then soared by 975.73% to $625000.0 in 2023, then tumbled by 65.0% to $218750.0 in 2024, then changed by 0.0% to $218750.0 in 2025.
  • The last three reported values for Convertible Debt were $218750.0 (Q1 2025), $218750.0 (Q4 2024), and $625000.0 (Q4 2023) per Business Quant data.